Reclassifying malignancy risk in indeterminate pulmonary nodules using Nodify Lung™ testing strategy

This presentation is sponsored by Biodesix, Inc.
This program will provide an overview of the Nodify Lung testing strategy, discuss case studies using the Nodify CDT™ and Nodify XL2™ tests and share recent data published from the ORACLE clinical study and real-world clinical use.
Dr. Pritchett will discuss how the testing strategy helps identify patients with a higher risk of malignancy who may be considered for timely intervention and those with a lower risk of malignancy who may be considered for CT surveillance.
Speaker: Michael Pritchett, DO, MPH, Director of Thoracic Oncology, Pulmonary and Critical Care Physician, President of the Society for Advanced Bronchology, Firsthealth of the Carolinas, and Pinehurst Medical Clinic
Opinions expressed and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.

[@pamreynolds6812]

For 2 years watched nodule went from 5 to 6mm. Now why wouldnt that be biopsied plus ground glass nodules